Efficacy and safety of zapnometinib in hospitalised adult patients with COVID-19 (RESPIRE): a randomised, double-blind, placebo-controlled, multicentre, proof-of-concept, phase 2 trial

https://www.thelancet.com/journals/eclinm/article/PIIS2589-5370(23)00414-5/fulltext?dgcid=hubspot_email_covidalerts&utm_campaign=covidalerts&utm_medium=email&_hsmi=280173067&_hsenc=p2ANqtz-8xiH4KaLWRAbZfBD8wZjFCupFtN2r6XrWzbMjN1sp6f9hW2fgWo-LNHPem1pJYRqif3NHecWm5zApVnuW553qgcu4TPA&utm_content=280145645&utm_source=hs_email